Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1328169 | 0.82 | GCK (1.00) | GCKSCN9ATRPV4HPGDALDH1A1 | |
| SCHEMBL190514 | 0.79 | GCK (0.44) | GCKSCN9APOLBKDRGAA | |
| SCHEMBL12126257 | 0.77 | GCK (0.63) | GCKTRPV4HPGDALDH1A1POLB | |
| SCHEMBL2340717 | 0.75 | GCK (0.67) | GCK | |
| SCHEMBL16429378 | 0.71 | GCK (0.55) | GCKSCN9AHPGDALDH1A1POLB | |
| SCHEMBL13439349 | 0.68 | GCK (0.43) | GCKALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1329540 | 0.66 | GCK (0.48) | GCKALDH1A1POLBNPC1RAB9A | |
| SCHEMBL15688114 | 0.66 | KDR (0.55) | GCKTRPV4ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL7054403 | 0.66 | GAA (0.64) | GCKHPGDALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL22583554 | 0.66 | KCNH2 (0.52) | GCKTRPV4ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2013-03-14 | — | — | US | claimed |
| US-8354540-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2013-01-15 | — | — | US | claimed |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-17 | — | — | US | claimed |
| EP-2013204-B1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2013204-B1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| EP-2543667-B1 | A method of preparing 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2543667-B1 | A method of preparing 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883828-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2543667-A9 | 2-aminopyridine analogs as glucokinase activators | Array Biopharma, Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-8022223-B2 | 2-aminopyridine analogs as glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2013204-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | GCK 1/4885SCN9A 1168/4885TRPV4 3161/4885 |
| US-20130065901-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885SCN9A 2492/4885TRPV4 3658/4885 |
| US-20110281874-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | GCK 1/4885SCN9A 2492/4885TRPV4 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.